Follicular Lymphoma - Pipeline Insight, 2025
Description
DelveInsight’s, “Follicular Lymphoma - Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Follicular Lymphoma: Overview
Follicular lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma (NHL) that arises from B lymphocytes, a type of white blood cell integral to the immune system. It is characterized by the formation of abnormal lymphoid follicles in lymph nodes and other lymphatic tissues. Accounting for about 20% of all NHL cases, FL typically presents with painless lymphadenopathy, often accompanied by symptoms like fatigue, night sweats, or unintentional weight loss in advanced stages. While generally considered indolent, FL can transform into a more aggressive form of lymphoma, necessitating vigilant monitoring. Advances in treatment, including immunotherapy and targeted therapies, have significantly improved outcomes for patients with this condition.
Common symptoms of FL include painless, swollen lymph nodes, often in the neck, armpits, or groin. Other common signs and symptoms include fatigue, unexplained weight loss, night sweats, and fever. Some individuals may also experience a feeling of fullness or discomfort in the abdomen due to an enlarged spleen or liver. Follicular lymphoma arises from the malignant transformation of B lymphocytes, a type of white blood cell, within the germinal centers of lymph nodes. The hallmark of its pathophysiology is the translocation of the BCL2 gene to the immunoglobulin heavy chain locus, most commonly t(14;18)(q32;q21), which leads to overexpression of the BCL2 protein. This protein prevents programmed cell death (apoptosis), allowing the abnormal B cells to survive longer than they should. As these cells accumulate, they form the characteristic follicular or nodular pattern seen in lymph nodes. This resistance to apoptosis, combined with the ability to evade the immune system, contributes to the indolent yet persistent nature of the disease.
The management of FL depends on the disease stage. Options available for the treatment of follicular lymphoma include radiation (RT), immunochemotherapy (Rituximab plus chemotherapy), Bundamustine with immunotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), immunochemotherapy plus RT, CVP (cyclophosphamide, vincristine, and prednisolone), single-agent rituximab, and observation until progression. The choice of regimen depends on the stage of the disease, preference of physician, and preference of the patient.
""Follicular Lymphoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Follicular Lymphoma pipeline landscape is provided which includes the disease overview and Follicular Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Follicular Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Follicular Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Follicular Lymphoma Emerging Drugs
MIL62 is self-developed by leveraging our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 demonstrates stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (other third-generation anti-CD20 antibody). The company is implementing critical clinical development strategies to first pursue marketing approval from the NMPA for the treatment of relapsed and/or refractory FL patients and DLBCL patients. At the same time, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab.
Further product details are provided in the report……..
Follicular Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Follicular Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Follicular Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular Lymphoma drugs.
Follicular Lymphoma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Follicular Lymphoma: Overview
Follicular lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma (NHL) that arises from B lymphocytes, a type of white blood cell integral to the immune system. It is characterized by the formation of abnormal lymphoid follicles in lymph nodes and other lymphatic tissues. Accounting for about 20% of all NHL cases, FL typically presents with painless lymphadenopathy, often accompanied by symptoms like fatigue, night sweats, or unintentional weight loss in advanced stages. While generally considered indolent, FL can transform into a more aggressive form of lymphoma, necessitating vigilant monitoring. Advances in treatment, including immunotherapy and targeted therapies, have significantly improved outcomes for patients with this condition.
Common symptoms of FL include painless, swollen lymph nodes, often in the neck, armpits, or groin. Other common signs and symptoms include fatigue, unexplained weight loss, night sweats, and fever. Some individuals may also experience a feeling of fullness or discomfort in the abdomen due to an enlarged spleen or liver. Follicular lymphoma arises from the malignant transformation of B lymphocytes, a type of white blood cell, within the germinal centers of lymph nodes. The hallmark of its pathophysiology is the translocation of the BCL2 gene to the immunoglobulin heavy chain locus, most commonly t(14;18)(q32;q21), which leads to overexpression of the BCL2 protein. This protein prevents programmed cell death (apoptosis), allowing the abnormal B cells to survive longer than they should. As these cells accumulate, they form the characteristic follicular or nodular pattern seen in lymph nodes. This resistance to apoptosis, combined with the ability to evade the immune system, contributes to the indolent yet persistent nature of the disease.
The management of FL depends on the disease stage. Options available for the treatment of follicular lymphoma include radiation (RT), immunochemotherapy (Rituximab plus chemotherapy), Bundamustine with immunotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), immunochemotherapy plus RT, CVP (cyclophosphamide, vincristine, and prednisolone), single-agent rituximab, and observation until progression. The choice of regimen depends on the stage of the disease, preference of physician, and preference of the patient.
""Follicular Lymphoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Follicular Lymphoma pipeline landscape is provided which includes the disease overview and Follicular Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Follicular Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Follicular Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Follicular Lymphoma.
This segment of the Follicular Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Follicular Lymphoma Emerging Drugs
- MIL62: MAB WORKS
MIL62 is self-developed by leveraging our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 demonstrates stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (other third-generation anti-CD20 antibody). The company is implementing critical clinical development strategies to first pursue marketing approval from the NMPA for the treatment of relapsed and/or refractory FL patients and DLBCL patients. At the same time, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab.
- AZD0486: AstraZeneca
- Abexinostat: Xynomic Pharmaceuticals
- ABBV-319: AbbVie
- NX-2127: Nurix Therapeutics, Inc.
Further product details are provided in the report……..
Follicular Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Follicular Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Follicular Lymphoma
- There are approx. 45+ key companies which are developing the therapies for Follicular Lymphoma. The companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, MAB WORKS and AstraZeneca.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Follicular Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular Lymphoma drugs.
Follicular Lymphoma Report Insights
- Follicular Lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Follicular Lymphoma drugs?
- How many Follicular Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular Lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Follicular Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Follicular Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mab Works
- AstraZeneca
- ADC Therapeutics
- Xynomic Pharmaceuticals
- AbbVie
- Nurix
- InnoCare Pharma
- LTZ Therapeutics
- Hutchmed
- Regeneron Pharmaceuticals
- Pfizer
- InnoCare Pharma
- TriSalus Life Sciences
- BeiGene
- MIL62
- AZD0486
- Acalabrutinib
- Loncastuximab tesirine
- Abexinostat
- ABBV-319
- NX-2127
- ICP 248
- LTZ-301
- HMPL-689
- Odronextamab
- PF-06821497
- ICP-248
- Nelitolimod
- Zanubrutinib
Table of Contents
150 Pages
- Introduction
- Executive Summary
- Follicular Lymphoma: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Follicular Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- MIL62: MAB WORKS
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Abexinostat: Xynomic Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ABBV-319: AbbVie
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Follicular Lymphoma Key Companies
- Follicular Lymphoma Key Products
- Follicular Lymphoma- Unmet Needs
- Follicular Lymphoma- Market Drivers and Barriers
- Follicular Lymphoma- Future Perspectives and Conclusion
- Follicular Lymphoma Analyst Views
- Follicular Lymphoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
